In vitro studies suggest a synergistic effect of aztreonam and CAZ-AVI for severe MDR bacterial infections with few therapeutic regimens available, such as MBL class B members including the New Delhi metallo-β-lactamase, VIM and imipenemase, and class D enzymes [39,40]. Here, VIM is linked to bacterial infectious disease.